Oxford Biotherapeutics Limited

Oxford BioTherapeutics (OBT) is focused on the development of targeted antibody-based medicines for oncology.  OBT's strategy is to develop innovative antibody-based cancer drugs, with integrated diagnositcs, against novel targets that it has discovered in its unique proteomic database.  Through its alliances with world leaders in antibody development (including Sanofi Aventis, GSK, Amgen, Seattle Genetics and Biowa) OBT is in an unrivalled position to convert its novel targets into an exciting pipeline of first-in-class therapeutics for the treatment of cancer.  OBT's pipeline will deliver cost-effective medicines to fulfill the major unmet medical need of cancer patients.

Why we like the business

OBT has a world leading database of oncology biomarkers and had begun to establish key strategic relationships that would be used to develop these novel targets.  There were also clear market drivers towards personalised medicine.